One in ten British adults used or interested in GLP-1 medications for weight loss owenhaskins Jan 8 4 min read In 2025, approximately 4.9 million British adults almost one in ten are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss
In-depth phylogenetic analysis of hepatitis C virus subtype 1a and occurrence of 80K and associated polymorphisms in the NS3 protease
In: Cryptorchidism: management and implications
Safety outcomes (adverse events) were synthesized descriptively because AE reporting was incomplete and not sufficiently consistent across trials to support quantitative synthesis
This graph diagrams utilization, unit cost, and cost as a percent of overall medical cost trend: note that by the middle of 2023, GLP-1 drug costs for Group health plan members comprised 13.6% of a major pharmacy benefit management (PBM) company, shown in the third bar
However, it is not a good alternative to surgery if your goal is to physically remove the skin